Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENA713 · 1 trial · 1 indication
The primary variable of this study is the percentage of patients having an AE leading to study drug discontinuation during the 24-week double-blind treatment period.
| Arm | Type | Description |
|---|---|---|
| 1 step | EXPERIMENTAL | - |
| 3 step | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Active Comparator | DRUG | 1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day. |
| ENA713 | DRUG | -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day. |
Inclusion Criteria: * A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria * A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria * An MMSE score of ≥ 10 and ≤ 20 at baseline Exclusion Criteria: * Any medical or neurological conditions other than AD t...
Top 20 of 24 competitors
ENA713 is a small molecule being developed by Novartis AG for the treatment of Alzheimer's Disease. It is currently in Phase 3 clinical development as an investigational therapy. The drug is being studied in patients with Alzheimer's Disease who have a Mini-Mental State Examination (MMSE) score between 10 and 20.
ENA713 is a small molecule developed for Alzheimer's Disease. The specific molecular target of ENA713 has not been disclosed in available clinical trial information. The drug is being evaluated for its effects on patients with Alzheimer's Disease in a Phase 3 clinical trial setting.
ENA713 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of ENA713 in patients with Alzheimer's Disease.
ENA713 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a completed Phase 3 clinical trial for the treatment of Alzheimer's Disease.
ENA713 has been studied in one clinical trial registered under the identifier NCT01614886. This was a randomized, double-blind, Phase 3 study conducted in Japan that evaluated the tolerability of two different titration methods of rivastigmine patch in Alzheimer's Disease patients. The trial enrolled 216 participants and has been completed.
ENA713 is being studied in a clinical trial that evaluates rivastigmine patch in Alzheimer's Disease patients. The trial title references rivastigmine patch, suggesting ENA713 may be related to or the same as rivastigmine, though the available information does not explicitly confirm this relationship.